TNF and psoriasis vulgaris: Infliximab, a TNF-α-binding antibody that is used to treat patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis (excluding localized type), and psoriatic erythroderma [54], has been shown to downregulate the production of anti-apoptotic proteins in regressing psoriatic skin [55].